Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation

Çelik, Burak

doi:10.2147/dddt.s150774

Cited by 46 publications

(33 citation statements)

References 39 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As ALG content in the formulation increased (formulation F3), the significantly (p<0.05) higher mucoadhesive properties were observed. This behavior was in agreement with the results published by Çelik [30], who indicated that the increase in ALG concentration resulted in higher mucoadhesion. The retention time evaluated in ex vivo and in vivo tests was found to be moderately low in film formulation P4, composed of only OLG (Table 4), which might be a result of low molecular weight, low viscosity, and low swelling ability of OLG [17].…”

Section: Mucoadhesive Propertiessupporting

confidence: 93%

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole

et al. 2019

View full text Add to dashboard Cite

Sodium alginate and its oligosaccharides through potential antifungal properties might improve the activity of antifungal drugs enhancing their efficacy and potentially reducing the frequency of application. Mucoadhesive buccal films are oral dosage forms designed for maintaining both local or systemic drug effects and seem to be a very promising alternative to conventional oral formulations. Hence, in this study, mucoadhesive buccal films based on the alginate and its oligosaccharide oligomer composed predominantly of mannuronic acid for the administration of posaconazole-antifungal drug from the azole group were developed. As the polymer gelation method, a relatively new freeze-thaw technique was chosen. All prepared formulations were examined for pharmaceutical tests, swelling, mechanical, and mucoadhesive properties. In addition, the influence of sodium alginate (ALG) and alginate oligosaccharides (OLG) on POS antifungal activity on Candida species was performed. It was observed that film formulation containing 1% ALG and 1% OLG (F2) was characterized by optimal mucoadhesive and swelling properties and prolonged drug release up to 5 h. Additionally, it was shown that OLG affected the growth reduction of all tested Candida spp. The obtained data has opened the way for future research for developing OLG-based dosage forms, which might increase the activity of antifungal drugs.

show abstract

Section: Mucoadhesive Propertiessupporting

confidence: 93%

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The same mucoadhesive drug delivery systems were created for riperidone, another atypical neuroleptic used to treat schizophrenia and bipolar disorder. A mucoadhesive buccal tablet formulation of risperidone allowed 90% release of the drug over 8 h, thereby providing direct systemic delivery of risperidone [ 143 ]. Risperidone-loaded solid lipid nanoparticles drug release and transport studies illustrated the advantages of oral delivery over poorly water-soluble drugs such as risperidone [ 144 , 145 ].…”

Section: Drug Delivery For Schizophrenia and Bipolar Disordersmentioning

confidence: 99%

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

et al. 2020

View full text Add to dashboard Cite

Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. One of the problem-solving methods is the usage of nanocontainer systems. In this review we summarized the data about nanoparticles drug delivery systems and their application for the treatment of neuropsychiatric disorders. Firstly, we described and characterized types of nanocarriers: inorganic nanoparticles, polymeric and lipid nanocarriers, their advantages and disadvantages. We discussed ways to interact with nerve tissue and methods of BBB penetration. We provided a summary of nanotechnology-based pharmacotherapy of schizophrenia, bipolar disorder, depression, anxiety disorder and Alzheimer’s disease, where development of nanocontainer drugs derives the most active. We described various experimental drugs for the treatment of Alzheimer’s disease that include vector nanocontainers targeted on β-amyloid or tau-protein. Integrally, nanoparticles can substantially improve the drug delivery as its implication can increase BBB permeability, the pharmacodynamics and bioavailability of applied drugs. Thus, nanotechnology is anticipated to overcome the limitations of existing pharmacotherapy of psychiatric disorders and to effectively combine various treatment modalities in that direction.

show abstract

“…For example, permeation enhancers (e.g., surfactants, bile salts, fatty acids, cyclodextrins, and chelators) have been shown to improve the mucosal permeability and absorption of various compounds (Tsutsumi et al, 1998; Shojaei et al, 1999; Bird et al, 2001; Burgalassi et al, 2006; Sohi et al, 2010; Tian et al, 2012; Prasanth et al, 2014; Patil and Devarajan, 2014; Ojewole et al, 2014; Marxen et al, 2018) by: (i) changing mucus rheology; (ii) increasing the fluidity of the lipid bilayer membrane; (iii) acting on the components at tight junctions; (iv) inhibiting mucosal enzymes; and (v) increasing the thermodynamic activity of drugs (Chinna Reddy and Chaitanya, 2011). In addition, the incorporation of mucoadhesive constituents has been demonstrated to enhance formulation retention time with the sublingual or buccal mucosa (Das and Das, 2004; Razafindratsita et al, 2007; Perioli and Pagano, 2013; Ikram et al, 2015; Yildiz Pekoz et al, 2016; El-Nabarawi et al, 2016; Ammar et al, 2017; Parodi et al, 2017; Celik, 2017; Salehi and Boddohi, 2017; Vasseur et al, 2017; Khan and Boateng, 2018; Razzaq et al, 2018; Sharma et al, 2018). This has been done primarily for solid dosage forms and semi-solid dosage forms.…”

Section: Sublingual and Buccal Formulations Approved And In Clinical mentioning

confidence: 99%

“…It has been evaluated for local drug delivery as a topical anesthetic in Phase I clinical studies. Furthermore, slow-disintegrating and non-disintegrating dosage forms, particularly for buccal drug delivery, have been extensively investigated in the literature to extend or control the release of active substances over a prolonged period (Scholz et al, 2008; Bahri-Najafi et al, 2014; Kaur et al, 2014; Jaipal et al, 2016; Celik, 2017; Lindert and Breitkreutz, 2017; Celik et al, 2017; Farag et al, 2018; Castro et al, 2018b). For example, multilayered films have been developed for controlled drug delivery and are generally designed to remain in their form and slowly release drug over a specified time (Lindert and Breitkreutz, 2017).…”

Section: Sublingual and Buccal Formulations Approved And In Clinical mentioning

confidence: 99%

Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration

Hua¹

2019

Front. Pharmacol.

118

View full text Add to dashboard Cite

The sublingual and buccal routes of administration have significant advantages for both local and systemic drug delivery. They have shown to be an effective alternative to the traditional oral route, especially when fast onset of action is required. Drugs can be rapidly and directly absorbed into the systemic circulation via venous drainage to the superior vena cava. Therefore, they are useful for drugs that undergo high hepatic clearance or degradation in the gastrointestinal tract, and for patients that have swallowing difficulties. Drugs administered via the sublingual and buccal routes are traditionally formulated as solid dosage forms (e.g., tablets, wafers, films, and patches), liquid dosage forms (e.g., sprays and drops), and semi-solid dosage forms (e.g., gels). Conventional dosage forms are commonly affected by physiological factors, which can reduce the contact of the formulation with the mucosa and lead to unpredictable drug absorption. There have been a number of advances in formulation development to improve the retention and absorption of drugs in the buccal and sublingual regions. This review will focus on the physiological aspects that influence buccal and sublingual drug delivery and the advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. The clinical development pipeline with formulations approved and in clinical trials will also be addressed.

show abstract

Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation

Cited by 46 publications

References 39 publications

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration

Contact Info

Product

Resources

About